Coliseum Capital, managed by Christopher Shackelton and Adam Gray, has recently disclosed an increase in its holding of BioScrip Inc (NASDAQ:BIOS). According to an amended filing with the Securities and Exchange Commission, the fund has acquired 4.2 million shares of common stock at a price of $2 per share as part of a public offering undertaken by BioScrip. As a result, the fund now controls approximately 23.2 million shares, which include 5.62 million shares of common stock and shares that could be obtained upon the conversion of preferred stock and warrants. The position would amount to roughly 17.6% of the company’s common stock.
A provider of infusion solutions, BioScrip Inc (NASDAQ:BIOS) has been in a steady uptrend since the start of the year, advancing by approximately 62% to yesterday’s closing price of $2.78 per share. On June 16, the company announced the pricing of the underwritten offering of 40 million shares of common stock at $2 per share, granting the underwriters the possibility to acquired an additional 5.2 million shares within the first 30 days after the offering. BioScrip expects to raise between $73.4 million and $83.2 million, depending on how the underwriters exercise their options. The company has also recently announced the acquisition of HS Infusion Holdings for $85 million, as part of its strategic development plan.
Elena Pavlovich/Shutterstock.com
Hedge fund sentiment towards BioScrip Inc (NASDAQ:BIOS) was unchanged during the first quarter: 13 elite hedge funds had this stock in their portfolio at the end of March, having together amassed 38% of the company’s outstanding stock. Philip Hempleman‘s Ardsley Partners held the largest position in BioScrip among the funds followed by Insider Monkey, having indicated ownership of 6.69 million shares in its latest 13F filing. Stephen Dubois‘ Camber Capital Management held 6.18 million shares of BioScrip at the end of March, up by 17% during the quarter.
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Coliseum Capital Management | 0 | 23,182,758 | 0 | 23,182,758 | 23,182,758 | 17.6% |
| Coliseum Capital | 8. | 17,841,112 | 0 | 17,841,112 | 17,841,112 | 14.0% |
| Coliseum Capital Partners | 0 | 14,553,786 | 0 | 14,553,786 | 14,553,786 | 11.6% |
| Coliseum Capital Partners II | 0 | 3,287,326 | 0 | 3,287,326 | 3,287,326 | 2.8% |
| Adam Gray | 0 | 23,182,758 | 0 | 23,182,758 | 23,182,758 | 17.6% |
| Christopher Shackelton | 0 | 23,182,758 | 0 | 23,182,758 | 23,182,758 | 17.6% |
Follow Christopher Shackelton And Adam Gray's Coliseum Capital
Page 1 of 10 – SEC Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
13D/A
Under the Securities Exchange Act of 1934*
(Amendment No. 3)
BioScrip,
Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
09069N108
(CUSIP Number)
Christopher Shackelton/Adam Gray
Metro Center
1 Station
Place, 7th Floor South
Stamford, CT 06902
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
June 22, 2016
(Date
of Event Which Requires Filing of this Statement)
If the filing person has
previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of sections 240.13d-1(e), 240.13d-1(f) or 140.13d-1(g), check the following box. ¨
The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities
Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
